Search results for: 'ma2a fuel develop deceleration'

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report ...

24 Dec 2020  |  North America  |  Market Research

North American Technology Benchmarking for OE Compliance for Fuel Economy, Growth Opportunity

Regulations Must Stabilize to Allow Effective Technology Strategies among OEMs for Improved Fuel Economy and Emissions

Infographics

×

Key Issues Addressed

The predominant driver of change in the automotive powertrain industry, and the need of the hour, is emissions reduction. Despite the social interest in powertrain electrification, the internal combustion engine (ICE) will remain the leading powertrain for at least 2 decades. Nonetheless, this primary propulsion unit offers scope for improvement, m...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This research service details the market findings witnessed in the North American aftermarket for fuel delivery systems.

Natural gas and diesel continue to be the predominant fuels for generator sets, however the proportions within the market attributed to each fuel are changing. The natural gas-fueled genset market is growing at a faster rate than the diesel-fueled market, however continues to lag behind in market share.

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

Examines the current marketing and distribution strategies within each market segment, with analysis of innovations, successes and failures, and a discussion of marketing and distribution challenges facing the industry.

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...